Arcutis Announces First Patient Enrolled in Phase IIa Clinical Trial Evaluating ARQ-252 as a Potential Treatment for Vitiligo

Arcutis Biotherapeutics, Inc. announced enrollment of the first patient in a Phase IIa clinical trial evaluating ARQ-252 as a potential treatment for vitiligo. ARQ-252 is a potent and highly selective topical small molecule inhibitor of Janus kinase type 1.